In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...

BTIG analyst Marie Thibault reiterated a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of $310.00. The ...

Wall Street is gearing up for another wave of blank check companies from seasoned and first-time sponsors, showing the ...

Virtual Meeting to be held on February 20 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

But before that let's have a chartist view from BTIG's technical guru Jonathan Krinsky. He notes that the S&P 500's rally off this week's lows is quite impressive and sets up the stock barometer ...